Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SATISH IDURU

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1417045311
CMS profile
336521
Location
BAYTOWN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$940.29

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $940.29 54

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SATISH IDURU

NPI 1417045311 · CMS profile ID 336521

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

BAYTOWN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417045311?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SATISH IDURU, NPI 1417045311, CMS profile ID 336521. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417045311?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SATISH IDURU, NPI 1417045311, CMS profile ID 336521. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417045311?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SATISH IDURU, NPI 1417045311, CMS profile ID 336521, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1417045311?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $940.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $29.3401/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819986869 CMS
Ferring Pharmaceuticals Inc. $19.4101/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 771564074 CMS
AbbVie Inc. $17.1401/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794907343 CMS
RedHill Biopharma Inc. $16.9301/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799925541 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $474.18 27
PY2020 $586.18 34
PY2021 $940.29 54
PY2022 $748.91 38
PY2023 $681.45 32
PY2024 $1,320.32 52
PY2025 $1,363.36 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $36,482.00 45
PY2024 Principal investigator $192,278.70 65
PY2023 Principal investigator $113,795.14 25
PY2022 Principal investigator $56,752.22 4
PY2021 Principal investigator $73,983.35 15
PY2020 Principal investigator $294,533.78 41
PY2019 Principal investigator $268,079.79 51

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736362
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736364
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736354
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736356
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/28/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736358
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/28/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736360
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/30/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736346
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/30/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736348
Principal investigator 1 Janssen Research & Development, LLC $5,157.00 09/11/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175283880
Principal investigator 1 Janssen Research & Development, LLC $126.00 09/11/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175283895
Principal investigator 1 Janssen Research & Development, LLC $5,157.00 09/11/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175283947
Principal investigator 1 Janssen Research & Development, LLC $126.00 09/11/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175283957
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 08/29/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736342
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/29/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736344
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 07/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736350
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736352
Principal investigator 1 Janssen Research & Development, LLC $2,467.00 07/17/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175283873
Principal investigator 1 Janssen Research & Development, LLC $2,467.00 07/17/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175283888
Principal investigator 1 Janssen Research & Development, LLC $127.00 07/17/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175283909
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 06/30/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736338
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 06/30/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736340
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/30/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736334
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 05/30/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736336
Principal investigator 1 Janssen Research & Development, LLC $3,598.00 05/28/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287456
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 04/30/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736330
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 04/30/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736332
Principal investigator 1 Janssen Research & Development, LLC $127.00 04/30/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175283941
Principal investigator 1 Janssen Research & Development, LLC $2,467.00 04/28/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175283902
Principal investigator 1 Janssen Research & Development, LLC $2,467.00 04/28/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175283917
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 03/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736326
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 03/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736328
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 02/28/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736322
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 02/28/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736324
Principal investigator 1 Bausch Health US, LLC $2,083.00 02/07/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224835602
Principal investigator 1 Bausch Health US, LLC $1,322.00 02/07/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224835608
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736314
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736316
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 01/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736318
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 01/31/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736320
Principal investigator 1 Janssen Research & Development, LLC $2,061.00 01/27/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175283963
Principal investigator 1 Bausch Health US, LLC $405.00 01/08/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224835606
Principal investigator 1 Janssen Research & Development, LLC $2,061.00 01/02/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175283925
Principal investigator 1 Janssen Research & Development, LLC $3,184.00 01/02/2025 Non-covered Recipient Entity
Accurate Clinic Rsrch Inc.
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175283932
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736310
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Ak Pain And Spine Center-Humble
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220736312